Cargando…

Corrigendum: Prevalence of Novel Psychoactive Substance (NPS) Use in Patients Admitted to Drug Detoxification Treatment

Detalles Bibliográficos
Autores principales:	Specka, Michael, Kuhlmann, Thomas, Sawazki, Jürgen, Bonnet, Udo, Steinert, Renate, Cybulska-Rycicki, Monika, Eich, Helmut, Zeiske, Benita, Niedersteberg, Antje, Schaaf, Luzia, Scherbaum, Norbert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Psychiatry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8098759/ https://www.ncbi.nlm.nih.gov/pubmed/33967867 http://dx.doi.org/10.3389/fpsyt.2021.681542

Ejemplares similares

Prevalence of Novel Psychoactive Substance (NPS) Use in Patients Admitted to Drug Detoxification Treatment
por: Specka, Michael, et al.
Publicado: (2020)

Novel Synthetic Opioids (NSO) Use in Opioid Dependents Entering Detoxification Treatment
por: Specka, Michael, et al.
Publicado: (2022)

Differences between users’ and addiction medicine experts’ harm and benefit assessments of licit and illicit psychoactive drugs: Input for psychoeducation and legalization/restriction debates
por: Bonnet, Udo, et al.
Publicado: (2022)

New Access Routes to Undertreated Populations; How Do Problem Substance Users Recruited from an Unemployment Office Differ from Detoxification Treatment Inpatients?
por: Scherbaum, Norbert, et al.
Publicado: (2021)

Ranking the Harm of Psychoactive Drugs Including Prescription Analgesics to Users and Others–A Perspective of German Addiction Medicine Experts
por: Bonnet, Udo, et al.
Publicado: (2020)

Cannabis use, abuse and dependence during the COVID-19 pandemic: a scoping review
por: Bonnet, Udo, et al.
Publicado: (2022)

The Dynamic Environment of Crypto Markets: The Lifespan of New Psychoactive Substances (NPS) and Vendors Selling NPS
por: Wadsworth, Elle, et al.
Publicado: (2018)

Novel Psychoactive Substances (NPS): a Study on Persian Language Websites
por: BIGDELI, Imanollah, et al.
Publicado: (2013)

Opiate maintenance patients’ attitudes and self-reported adherence to protective measures against SARS-CoV-2 infections
por: Specka, Michael, et al.
Publicado: (2023)

Hair analysis for New Psychoactive Substances (NPS): Still far from becoming the tool to study NPS spread in the community?
por: Florou, Dimitra, et al.
Publicado: (2021)

Suicidality and self-injury behaviours due to the use of Novel Psychoactive Substances (NPS)
por: Orsolini, L.
Publicado: (2023)

Is the Urine Cannabinoid Level Measured via a Commercial Point-of-Care Semiquantitative Immunoassay a Cannabis Withdrawal Syndrome Severity Predictor?
por: Claus, Benedikt Bernd, et al.
Publicado: (2020)

Abuse of Prescription Drugs in the Context of Novel Psychoactive Substances (NPS): A Systematic Review
por: Schifano, Fabrizio, et al.
Publicado: (2018)

Recent Changes in Drug Abuse Scenarios: The New/Novel Psychoactive Substances (NPS) Phenomenon
por: Schifano, Fabrizio
Publicado: (2018)

Sales and Advertising Channels of New Psychoactive Substances (NPS): Internet, Social Networks, and Smartphone Apps
por: Miliano, Cristina, et al.
Publicado: (2018)

Analyzing the Open/Deep Web to Better Understand the New/Novel Psychoactive Substances (NPS) Scenarios: Suggestions from CASSANDRA and NPS.Finder Research Projects
por: Schifano, Fabrizio
Publicado: (2020)

Neuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants
por: Miliano, Cristina, et al.
Publicado: (2016)

The prevalence of novel psychoactive substances (NPS) use in non-clinical populations: a systematic review protocol
por: Khaled, Salma M., et al.
Publicado: (2016)

EDITORIAL: New Psychoactive Substances (NPS), a New Global Issue: Neuropharmacological, Chemical and Toxicological Aspects
por: Pichini, Simona, et al.
Publicado: (2017)

Rapid Detection and Quantification of Novel Psychoactive Substances (NPS) Using Raman Spectroscopy and Surface-Enhanced Raman Scattering
por: Muhamadali, Howbeer, et al.
Publicado: (2019)

Clinical Presentations and Predictors of In-Hospital Mortality in Illicit Drug Users in the New Psychoactive Substances (NPS) Endemic Era in Taiwan
por: Yeh, Hsin-Tzu, et al.
Publicado: (2022)

Mechanistic Insights into the Stimulant Properties of Novel Psychoactive Substances (NPS) and Their Discrimination by the Dopamine Transporter—In Silico and In Vitro Exploration of Dissociative Diarylethylamines
por: Sahai, Michelle A., et al.
Publicado: (2018)

The Role of Dopamine in the Stimulant Characteristics of Novel Psychoactive Substances (NPS)—Neurobiological and Computational Assessment Using the Case of Desoxypipradrol (2-DPMP)
por: Loi, Barbara, et al.
Publicado: (2020)

Drug trends and harm related to new psychoactive substances (NPS) in Sweden from 2010 to 2016: Experiences from the STRIDA project
por: Helander, Anders, et al.
Publicado: (2020)

Molecular Mechanisms of Action of Novel Psychoactive Substances (NPS). A New Threat for Young Drug Users with Forensic-Toxicological Implications
por: Giorgetti, Arianna, et al.
Publicado: (2021)

Establishment of Neurotoxicity Assessment Using Microelectrode Array (MEA) with hiPSC-Derived Neurons and Evaluation of New Psychoactive Substances (NPS)
por: Kang, Kyu-ree, et al.
Publicado: (2022)

Availability of Illegal Drugs During the COVID-19 Pandemic in Western Germany
por: Scherbaum, Norbert, et al.
Publicado: (2021)

Analysis of Relationships between DAT1 Polymorphism Variants, Personality Dimensions, and Anxiety in New Psychoactive Substance (Designer Drug) (NPS) Users
por: Chmielowiec, Jolanta, et al.
Publicado: (2021)

Gabapentinoid-related deaths: An alarming global trend or just a special challenge within the long tail of the giant opioid epidemic?
por: Bonnet, Udo, et al.
Publicado: (2022)

Health and Social Problems Associated with Recent Novel Psychoactive Substance (NPS) Use Amongst Marginalised, Nightlife and Online Users in Six European Countries
por: Van Hout, Marie Claire, et al.
Publicado: (2017)

Corrigendum to ”HighResNPS.com: An Online Crowd-Sourced HR-MS Database for Suspect and Non-targeted Screening of New Psychoactive Substances”
por: Mardal, Marie, et al.
Publicado: (2019)

New psychoactive substances (NPS) in the Netherlands: occurrence in forensic drug samples, consumer drug samples and poisons center exposures between 2013 and 2017
por: Hondebrink, Laura, et al.
Publicado: (2020)

Comment on “Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update”
por: Bonnet, Udo, et al.
Publicado: (2021)

Screening of new psychoactive substances (NPS) by gas-chromatography/time of flight mass spectrometry (GC/MS-TOF) and application to 63 cases of judicial seizure
por: Dei Cas, Michele, et al.
Publicado: (2019)

In Silico Investigations into the Selectivity of Psychoactive and New Psychoactive Substances in Monoamine Transporters
por: Botha, Michelle J., et al.
Publicado: (2022)

Cannabinoids in the Treatment of Cannabis Use Disorder: Systematic Review of Randomized Controlled Trials
por: Vuilleumier, Caroline, et al.
Publicado: (2022)

Editorial: New Trends of Substance Abuse: Looking for New Psychotropic Effects of Chem Sex Drugs, Cognitive Enhancers, and New Psychoactive Substances
por: Pichini, Simona, et al.
Publicado: (2020)

Quality of Life in Patients with Substance Use Disorders Admitted to Detoxification Compared with Those Admitted to Hospitals for Medical Disorders: Follow-Up Results
por: Vederhus, John-Kåre, et al.
Publicado: (2016)

Psychoactive drugs and driving
por: Parekh, Vanita
Publicado: (2019)

Diagnostic capabilities of self-reported psychoactive substance use among patients admitted to psychiatric consultations in Benin, West Africa
por: Abdelhakim, Ahmat K., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v6llu30uo7innpkudkjm6tjein